Effects of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial

Trial Profile

Effects of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Eplerenone (Primary)
  • Indications Primary hyperparathyroidism
  • Focus Therapeutic Use
  • Acronyms EPATH
  • Most Recent Events

    • 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association
    • 13 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top